Page last updated: 2024-08-24

triazoles and baclofen

triazoles has been researched along with baclofen in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Nikbakht, MR; Stone, TW	1
Anderson, R; Carlson, G; Gandal, MJ; Gur, RE; Jonak, G; Klook, K; Leitman, V; Liang, Y; Ortinski, PI; Pierce, RC; Siegel, SJ; Sisti, J; Thieu, T	1
Ang, D; De Santis, A; Pauwels, A; Scarpellini, E; Tack, J; Vanuytsel, T	1

Reviews

1 review(s) available for triazoles and baclofen

Article	Year
Management of refractory typical GERD symptoms. Nature reviews. Gastroenterology & hepatology, 2016, Volume: 13, Issue:5 Topics: Alginates; Algorithms; Antacids; Baclofen; Chronic Disease; Esophagoscopy; Gastroesophageal Reflux; Gastrointestinal Agents; Gastroscopy; Humans; Isoxazoles; Muscle Relaxants, Central; Neurotransmitter Agents; Phosphinic Acids; Propylamines; Triazoles	2016

Other Studies

2 other study(ies) available for triazoles and baclofen

Article	Year
Suppression of presynaptic responses to adenosine by activation of NMDA receptors. European journal of pharmacology, 2001, Sep-07, Volume: 427, Issue:1 Topics: Action Potentials; Adenosine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Baclofen; Dose-Response Relationship, Drug; Excitatory Amino Acid Agonists; GABA Agonists; Glycine; Hippocampus; In Vitro Techniques; Kainic Acid; Long-Term Potentiation; Male; N-Methylaspartate; Phenethylamines; Presynaptic Terminals; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Rats; Rats, Wistar; Receptor, Adenosine A2A; Receptors, N-Methyl-D-Aspartate; Time Factors; Triazines; Triazoles	2001
GABAB-mediated rescue of altered excitatory-inhibitory balance, gamma synchrony and behavioral deficits following constitutive NMDAR-hypofunction. Translational psychiatry, 2012, Jul-17, Volume: 2 Topics: Animals; Autistic Disorder; Baclofen; Disease Models, Animal; Evoked Potentials, Auditory; Exploratory Behavior; Fluorobenzenes; GABA-B Receptor Agonists; In Situ Hybridization; Intellectual Disability; Interneurons; Male; Mice; Mice, Transgenic; Parvalbumins; Phenotype; Pyramidal Cells; Receptors, N-Methyl-D-Aspartate; Risperidone; Schizophrenia; Social Behavior; Synaptic Potentials; Triazoles	2012

Article

Year

Suppression of presynaptic responses to adenosine by activation of NMDA receptors.

European journal of pharmacology, 2001, Sep-07, Volume: 427, Issue:1

Topics: Action Potentials; Adenosine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Baclofen; Dose-Response Relationship, Drug; Excitatory Amino Acid Agonists; GABA Agonists; Glycine; Hippocampus; In Vitro Techniques; Kainic Acid; Long-Term Potentiation; Male; N-Methylaspartate; Phenethylamines; Presynaptic Terminals; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Rats; Rats, Wistar; Receptor, Adenosine A2A; Receptors, N-Methyl-D-Aspartate; Time Factors; Triazines; Triazoles

2001

GABAB-mediated rescue of altered excitatory-inhibitory balance, gamma synchrony and behavioral deficits following constitutive NMDAR-hypofunction.

Translational psychiatry, 2012, Jul-17, Volume: 2

Topics: Animals; Autistic Disorder; Baclofen; Disease Models, Animal; Evoked Potentials, Auditory; Exploratory Behavior; Fluorobenzenes; GABA-B Receptor Agonists; In Situ Hybridization; Intellectual Disability; Interneurons; Male; Mice; Mice, Transgenic; Parvalbumins; Phenotype; Pyramidal Cells; Receptors, N-Methyl-D-Aspartate; Risperidone; Schizophrenia; Social Behavior; Synaptic Potentials; Triazoles

2012